X4 Pharmaceuticals, Inc.

XFOR Healthcare Biotechnology

In the quarter to June 2026, revenue grew 346.3%, EPS grew 96.3%, free cash flow grew 13.8% and total debt rose 1.21%, each against the same quarter a year earlier.

2.59 0.05 −1.89%
Market cap
$261.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
n/a
Altman Z
−1.78
Beneish M
8.05
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(156.87%) (75.99%) (104.21%) (113.08%)
ROA
(55.66%) (36.25%) (49.82%) (50.32%)
ROIC
(399.12%) (566.65%) (543.03%) (226.62%)
Return on Tangible Assets
(86.83%) (33.56%) (45.67%) (45.16%)
Average Days of Receivables
17.25 5.96 45.07 47.15
Free Cash Flow per Share
(2.45) (2.10) (0.74) (0.70)
Free Cash Flow
(106.09) (88.62) (92.85) (88.74)
Other line items

Show all line items

Columns are period end dates